Evaluation of the efficacy and safety of Escherichia coli-derived recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion to treat degenerative spinal disease: a protocol of prospective, randomized controlled, assessor-blinded, open-label, multicenter trial

BACKGROUND: Recombinant human bone morphogenetic protein-2 (rhBMP-2) has been widely used as an alternative bone graft in spine fusion surgery. However, clinical outcome such as effects and complications has not yet been revealed for transforaminal lumbar interbody fusion (TLIF). Although previous s...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Jun-Young, Park, Hyun-Jin, Park, Sang-Min, Kang, Chang-Nam, Song, Kwang-Sup
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429459/
https://www.ncbi.nlm.nih.gov/pubmed/36045371
http://dx.doi.org/10.1186/s13018-022-03289-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429459/
https://www.ncbi.nlm.nih.gov/pubmed/36045371
http://dx.doi.org/10.1186/s13018-022-03289-w

Ejemplares similares